| __timestamp | Amphastar Pharmaceuticals, Inc. | Celldex Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 159205000 | 101881000 |
| Thursday, January 1, 2015 | 174172000 | 4011000 |
| Friday, January 1, 2016 | 150976000 | 102026000 |
| Sunday, January 1, 2017 | 149380000 | 96171000 |
| Monday, January 1, 2018 | 187681000 | 66449000 |
| Tuesday, January 1, 2019 | 190434000 | 42672000 |
| Wednesday, January 1, 2020 | 206506000 | 42534000 |
| Friday, January 1, 2021 | 238029000 | 3068000 |
| Saturday, January 1, 2022 | 250127000 | 1400000 |
| Sunday, January 1, 2023 | 293274000 | 3008000 |
Cracking the code
In the competitive landscape of pharmaceuticals, cost efficiency is paramount. Amphastar Pharmaceuticals, Inc. and Celldex Therapeutics, Inc. have shown contrasting trends in their cost of revenue from 2014 to 2023. Amphastar has consistently increased its cost of revenue, peaking at approximately $293 million in 2023, reflecting a growth of over 84% from 2014. This suggests a robust expansion strategy, possibly driven by increased production or new product lines.
Conversely, Celldex's cost of revenue has dramatically decreased, plummeting by nearly 97% over the same period. This sharp decline could indicate a strategic pivot, perhaps focusing on more cost-effective operations or a shift away from revenue-intensive products. These trends highlight the diverse strategies within the pharmaceutical industry, where companies must balance growth with cost efficiency to thrive.
Cost of Revenue Trends: Eli Lilly and Company vs Celldex Therapeutics, Inc.
Analyzing Cost of Revenue: Johnson & Johnson and Amphastar Pharmaceuticals, Inc.
Cost of Revenue Trends: Sanofi vs Amphastar Pharmaceuticals, Inc.
Cost Insights: Breaking Down Bio-Techne Corporation and Amphastar Pharmaceuticals, Inc.'s Expenses
Bio-Techne Corporation vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Veracyte, Inc. vs Amphastar Pharmaceuticals, Inc.
Cost Insights: Breaking Down Xenon Pharmaceuticals Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
MorphoSys AG vs Amphastar Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Breaking Down Revenue Trends: Amphastar Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.
Cost of Revenue: Key Insights for Amphastar Pharmaceuticals, Inc. and Evotec SE
Analyzing Cost of Revenue: Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Celldex Therapeutics, Inc. vs MiMedx Group, Inc.